Table 1.

Sample summary and clinical results

						Pre-treatment				Post-treatment				Fold change
ID	TNM	Ki67	Grade	ER/PR	HER2	sTIL H&E (%)	sTIL mIF* (count/pixel)	PD-L1 mIF* (count/pixel)	PD-L1 SP142	sTIL H&E (%)	sTIL mIF* (count/pixel)	PD-L1 mIF* (count/pixel)	PD-L1 SP142	sTIL H&E	PD-L1 SP142
1	pT1c, N1	11%	2	+/+ (100%/100%)	–	8.75	0.48	0.07	IC0	12.5	0.59	0.13	IC0	+ 0.4	0
2	pT2c, pN2	19%	2	+/+ (96%/90%)	–	13.75	1.35	1.04	IC0	20	1.53	0.87	n/a	+ 0.5	n/a
3	pT2, N1	17%	2	+/+ (98%/100%)	–	1.75	0.13	0.07	IC0	1.75	1.25	0.35	IC1	0	+ 1
4	pT2N1	75%	3	−/− (0%/0%)	+	6.25	0.23	0.24	IC1	10	0.74	0.68	IC2	+ 0.6	+ 1
5	pT1c, N1	7%	1	+/+ (98%/92%)	–	3.75	0.88	0.18	IC0	5	0.34	0.09	IC1	+ 0.3	+ 1
6	T2, N1	73%	3	−/− (0%/0%)	+	18.75	0.84	0.01	IC0	18.75	0.94	0.40	IC0	0	0
7	T2, N1	55%	3	+/+ (98%/100%)	–	18.75	1.18	0.54	IC1	20	1.24	0.64	n/a	+ 0.1	n/a
8	pT2, N0	50%	3	+/+ (100%/42%)	–	7.5	1.28	0.97	IC1	16.25	1.68	1.30	IC1	+ 1.2	0
9	pT1b, pN0	11%	2	+/+ (100%/100%)	–	1	0.06	0.06	IC0	5	0.27	0.23	IC0	+ 4	0
10	T1c, N0	33%	2	+/+ (100%/99%)	–	11.5	0.41	0.38	IC1	18.75	1.48	1.33	IC3	+ 0.6	+ 2
11	pT1c, pN1a	38%	3	+/− (69%/0%)	+	6.25	0.35	0.22	IC1	5	1.59	0.65	IC2	−0.2	+ 1
12	pT2, N0	12%	3	+/+ (98%/100%)	+	61.25	2.21	1.81	IC1	72.5	3.52	1.99	IC3	+ 0.2	+ 2
13	pT2, pN0	87%	3	+/+ (100%/7%)	–	31.25	1.69	0.06	IC1	55	1.77	0.98	IC3	+ 0.8	+ 2
14	N/A	N/A	1	+/+ (100%/100%)	–	1	n/a	n/a	n/a	1	n/a	n/a	n/a	0	n/a
15	pT1c, N0	30%	2	+/+ (100%/50%)	–	3.5	1.26	n/a	IC0	7	1.14	0.76	IC2	+ 1	+ 2
16	pT1b, N0	95%	3	−/− (0%/0%)	–	1	0.38	0.03	IC0	13.75	0.99	0.06	IC3	+ 12.8	+ 3

TNM stage by the TNM Classification of Malignant Tumors, Ki67% of Ki67-positive tumor cells, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, sTIL stromal tumor-infiltrating lymphocyte, H&E hematoxylin and eosin stain, PD-L1 programmed death ligand 1, SP142 Ventana PD-L1 assay, IC immune cell; *× 10⁻³